Marching Toward Progress - priME Oncology

Marching Toward Progress

Checkpoint Inhibitors in the Treatment of NSCLC

Not a member of My prIME? Join now for instant access.

Keep up to date on the latest information on immunotherapy, patient identification, adverse event management, and treatment selection, specifically within the veteran population with lung cancer. And increase your immunotherapy knowledge with a case presentation and follow-up discussion.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



1.0 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Jun 17, 2019

Expiration Date

Jun 17, 2020

Marching Toward Progress: Checkpoint Inhibitors in the Treatment of NSCLC
Suresh Ramalingam, MD

  • Suresh Ramalingam, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States

This educational activity is designed to meet the needs of medical, surgical, and radiation oncologists, as well as advanced practitioners and midlevel providers, who treat/manage patients with lung cancer in the VA system or in the VA choice programs.

After successful completion of this educational activity, participants should be able to:

  • Understand key components of the immune system and the biochemistry associated with checkpoint blockade, including specific inhibitors of PD-1/PD-L1 and CTLA-4
  • Implement effective strategies for integrating checkpoint inhibitors into the treatment of non-small cell lung cancer (NSCLC)
  • Develop treatment plans to manage both common and rare immune-related adverse events (irAEs) associated with the use of checkpoint inhibitors in lung cancer

This educational activity is supported by a grant from Merck and Co, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 1.0 hour

To contact Postgraduate Institute for Medicine please visit

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Ramalingam has disclosed that he has received consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Lilly, Loxo, Genentech, Merck, and Takeda. He also disclosed contracted research for Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
  • Trudy Stoddert, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.